NCCN Guidelines Insights: Cancer-Associated Venous Thromboembolic Disease, Version 2.2018.
Publication
, Journal Article
Streiff, MB; Holmstrom, B; Angelini, D; Ashrani, A; Bockenstedt, PL; Chesney, C; Fanikos, J; Fenninger, RB; Fogerty, AE; Gao, S; Goldhaber, SZ ...
Published in: J Natl Compr Canc Netw
November 2018
Venous thromboembolism (VTE) is common in patients with cancer and increases morbidity and mortality. VTE prevention and treatment are more complex in patients with cancer. The NCCN Guidelines for Cancer-Associated Venous Thromboembolic Disease outline strategies for treatment and prevention of VTE in adult patients diagnosed with cancer or in whom cancer is clinically suspected. These NCCN Guidelines Insights explain recent changes in anticoagulants recommended for the treatment of cancer-associated VTE.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
J Natl Compr Canc Netw
DOI
EISSN
1540-1413
Publication Date
November 2018
Volume
16
Issue
11
Start / End Page
1289 / 1303
Location
United States
Related Subject Headings
- Venous Thromboembolism
- United States
- Treatment Outcome
- Time Factors
- Survival Analysis
- Societies, Medical
- Randomized Controlled Trials as Topic
- Patient Selection
- Oncology & Carcinogenesis
- Neoplasms
Citation
APA
Chicago
ICMJE
MLA
NLM
Streiff, M. B., Holmstrom, B., Angelini, D., Ashrani, A., Bockenstedt, P. L., Chesney, C., … Engh, A. M. (2018). NCCN Guidelines Insights: Cancer-Associated Venous Thromboembolic Disease, Version 2.2018. J Natl Compr Canc Netw, 16(11), 1289–1303. https://doi.org/10.6004/jnccn.2018.0084
Streiff, Michael B., Bjorn Holmstrom, Dana Angelini, Aneel Ashrani, Paula L. Bockenstedt, Carolyn Chesney, John Fanikos, et al. “NCCN Guidelines Insights: Cancer-Associated Venous Thromboembolic Disease, Version 2.2018.” J Natl Compr Canc Netw 16, no. 11 (November 2018): 1289–1303. https://doi.org/10.6004/jnccn.2018.0084.
Streiff MB, Holmstrom B, Angelini D, Ashrani A, Bockenstedt PL, Chesney C, et al. NCCN Guidelines Insights: Cancer-Associated Venous Thromboembolic Disease, Version 2.2018. J Natl Compr Canc Netw. 2018 Nov;16(11):1289–303.
Streiff, Michael B., et al. “NCCN Guidelines Insights: Cancer-Associated Venous Thromboembolic Disease, Version 2.2018.” J Natl Compr Canc Netw, vol. 16, no. 11, Nov. 2018, pp. 1289–303. Pubmed, doi:10.6004/jnccn.2018.0084.
Streiff MB, Holmstrom B, Angelini D, Ashrani A, Bockenstedt PL, Chesney C, Fanikos J, Fenninger RB, Fogerty AE, Gao S, Goldhaber SZ, Gundabolu K, Hendrie P, Lee AI, Lee JT, Mann J, McMahon B, Millenson MM, Morton C, Ortel TL, Ozair S, Paschal R, Shattil S, Siddiqi T, Smock KJ, Soff G, Wang T-F, Williams E, Zakarija A, Hammond L, Dwyer MA, Engh AM. NCCN Guidelines Insights: Cancer-Associated Venous Thromboembolic Disease, Version 2.2018. J Natl Compr Canc Netw. 2018 Nov;16(11):1289–1303.
Published In
J Natl Compr Canc Netw
DOI
EISSN
1540-1413
Publication Date
November 2018
Volume
16
Issue
11
Start / End Page
1289 / 1303
Location
United States
Related Subject Headings
- Venous Thromboembolism
- United States
- Treatment Outcome
- Time Factors
- Survival Analysis
- Societies, Medical
- Randomized Controlled Trials as Topic
- Patient Selection
- Oncology & Carcinogenesis
- Neoplasms